Guidelines for clinical application of platinum drugs in breast cancer (2023 edition) / 中华肿瘤杂志

Breast cancer is the most common malignant tumor in women around the world, and it is also a common cause of death in female patients with malignant tumors in China, which seriously harms women's health. At present, with the application of comprehensive treatment approaches, breast cancer has become one of the most effective solid tumors. Platinum drugs are widely used in malignant tumors, and they are also commonly used as effective chemotherapeutic drugs for breast cancer. To regulate the application of platinum drugs in breast cancer, the experts from Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, discuss and approve the "Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)" . This guideline is developed from the "Expert consensus on the clinical application of platinums in advanced breast cancer (2020 version)" , which is updated from the latest evidence based on breast cancer at home and abroad, for platinum drugs in breast cancer clinical use, application scheme, efficacy analysis and treatment of adverse effects. This guideline aims to guide clinicians to use drugs rationally, and to further standardize the diagnosis and treatment.

Research progress and coping strategy of the drug resistant mechanism of platinum anti-tumor drugs / 药学实践杂志

Platinum anti-tumor drugs are currently the most widely used first-line chemotherapeutic drugs in clinical practice, and their curative effects are remarkable. However, the problems of platinum drug resistance in non-small cell lung cancer, breast cancer, ovarian cancer and others seriously limit effectiveness and clinical application of platinum drugs. The occurrence of platinum drug resistance is caused by many factors. At present, the resistance mechanism of platinum drugs mainly includes the following aspects: decreasing the accumulation of platinum in cells, increasing the inactivation of platinum in cells, repairing DNA damage and tumor cell apoptosis inactivation. This article reviews the drug resistance mechanism and coping strategy of platinum anti-tumor drugs, providing ideas for the development of platinum anti-tumor drugs and references for overcoming clinical platinum drug resistance.

Evaluation of efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer patients aged 70 years or over / 肿瘤

Objective: To evaluate the efficacy and safety of platinum-based doublet chemotherapy for patients aged ≥70 years old with advanced non-small cell lung cancer (NSCLC). Methods: One hundred and sixty-seven patients with NSCLC at stage III/IV were divided into three groups: patients aged ≥70 years old receiving platinum-based doublet chemotherapy (group A), patients aged ≥70 years old receiving best supportive care (group B) and patients aged <70 years old receiving platinum-based doublet chemotherapy (group C). At least two cycles of chemotherapy were required. The short-term response and the adverse effects were observed. All patients were followed up, and the progression-free survival (PFS) and the overall survival (OS) were calculated. Results: There were no significant differences in short-term response rate (33.3% vs 35.5%, P=0.811), median PFS (124 d vs 140 d, P=0.122) and median survival (337 d vs 367 d, P=0.173) between group A and group C. The median PFS and median survival of group B were 87 d and 218 d, respectively, which were both shorter than those of group A and group C (P<0.05). The one-year survival rate (42% vs 53%) and the rate of Eastern Cooperative Oncology Group performance status (ECOG PS) score improvement (41% vs 48%) after chemotherapy between group A and group C were not significantly different, but the group B had a lower one-year survival rate (15%) and a lower ECOG PS score improvement rate (13%) as compared with group A and group C (P<0.05). The incidence rates of grade III/IV leukopenia and nausea/vomiting were similar in group A and group C. Conclusion: The elderly patients (≥70 years old) with advanced NSCLC, whose ECOG PS score was ≤2, may benefit from the platinum-based doublet chemotherapy, and the short-term response, survival and the improvement in life quality of these patients were similar to the patients younger than 70 years old with advanced NSCLC receiving the same chemotherapy. The side effects of chemotherapy occurred in the elderly and non-elderly patients were also similar. Copyright© 2011 by TUMOR.